ImmunityBio reports Q1 EPS (15c), consensus (14c)

Reports Q1 revenue $16.5M, consensus $16.6M. “We are seeing a steady growth in revenue as urologists increase their use of ANKTIVA to treat NMIBC carcinoma in situ patients, particularly since we addressed the BCG shortage with the launch of our rBCG EAP in February,” said Richard Adcock, President and CEO of ImmunityBio (IBRX). “Nearly 200 urological practices are in early stages of implementation or have already begun administering rBCG to patients, many of them in rural areas where patients otherwise would not have access to this treatment. This not only lets us help more patients, it opens a new marketplace for ImmunityBio’s therapies.”